Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Baxter
Harvard Business School
Medtronic
AstraZeneca

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Tetraphase Pharms Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for TETRAPHASE PHARMS, and what generic alternatives to TETRAPHASE PHARMS drugs are available?

TETRAPHASE PHARMS has one approved drug.

There are two US patents protecting TETRAPHASE PHARMS drugs.

There are fifty-seven patent family members on TETRAPHASE PHARMS drugs in twenty-nine countries and eight supplementary protection certificates in seven countries.

Summary for Tetraphase Pharms
International Patents:57
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Tetraphase Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes 8,796,245   Start Trial   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes 8,906,887   Start Trial Y   Start Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Tetraphase Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2323972 CA 2019 00009 Denmark   Start Trial PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
2323972 122019000024 Germany   Start Trial PRODUCT NAME: ERAVACYCLINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920
2323972 PA2019009 Lithuania   Start Trial PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920
2323972 12/2019 Austria   Start Trial PRODUCT NAME: ERAVACYCLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 (MITTEILUNG) 20180924
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
Johnson and Johnson
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.